While the company reports its initiatives are starting to pay off, its Q3 filings show several areas of financial strain.

Charles River Laboratories presents with optimistic growth expectations that seem a stretch given the business's current performance. See why CRL stock is a Hold.

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

Farther Finance Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

Charles River Laboratories, a Wilmington, Mass., pharma services giant, is closing a Skokie office that will result in the ...

Charles River Laboratories Intl ( (CRL)) has released its Q3 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors. Charles River Laboratories ...

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and ...

Dozens of researchers across Canada have joined a growing chorus of voices urging the federal government to halt the ...

By Sam Boughedda Charles River Laboratories (NYSE:CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from ...